[Featured Stock] Ilyang Pharmaceutical Rises on Collaboration with Professor Park Mansung for World's First Discovery of COVID-19 Targeted Treatment Factor

[Asia Economy Reporter Minwoo Lee] Ilyang Pharmaceutical's stock price is on the rise. It appears that the fact they have collaborated with a research team that discovered the key factor controlling the spread of the COVID-19 virus, the first in the world, has been highlighted.

As of 10:19 AM on the 26th, Ilyang Pharmaceutical's stock price recorded 35,050 KRW, up 3.85% compared to the previous day. The collaboration history with the research team that developed the controlling factor to prevent the spread of the COVID-19 virus seems to have been emphasized.

The day before, the National Research Foundation of Korea announced that a joint research team of Professors Mansung Park and Yoonki Kim from Korea University and Professor Daehyun Baek from Seoul National University completed a high-resolution map showing the expression patterns of the viral genome over time after infection by 'SARS-CoV-2,' the cause of COVID-19. Based on the SARS-CoV-2 translation map, the research team discovered a new factor regulating the efficiency of viral protein production and named it 'TIS-L.' This research result was also published in the international academic journal Nature Communications (dated the 25th). Professor Mansung Park of Korea University said, "This research result will help understand the infection mechanism of SARS-CoV-2 and contribute to COVID-19 therapeutic research targeting 'TIS-L.'"

Meanwhile, last year, Ilyang Pharmaceutical requested the 'BSL-3 Facility Research Team' at the Biosafety Center of Korea University College of Medicine to conduct tests on MERS therapeutic candidate substances and Supect against the COVID-19 virus. Professor Mansung Park serves as the director of the Biosafety Center. Previously, in 2014, Ilyang Pharmaceutical signed a memorandum of understanding (MOU) for R&D mutual cooperation with Korea University College of Medicine and collaborated.

Ilyang Pharmaceutical stated, "Currently, there are no ongoing matters related to COVID-19 therapeutics."